Results

Most recent

AMD-Non-Neovascular

1–7 of 7 results for elamipretide

Platform for Screening Compounds for Treatment of AMD Using iPSC-derived human RPE: Examples Using Elamipretide and SBT-272
Lucian V. Del Priore, MD, PhD
Annual Meeting Talks
2022
ReCLAIM-2: Phase 2 Trial of Subcutaneous Elamipretide in Patients with Noncentral Geographic Atrophy
Jeffrey S. Heier, MD
Annual Meeting Talks
2022
Safety and Efficacy of SC Elamipretide to Treat Noncentral Geographic Atrophy: ReCLAIM-1 Results and Phase II ReCLAIM-2 Baseline Characteristics
David R Lally, MD
Annual Meeting Talks
2021
Effects of the Mitochondria-Targeted Drug Elamipretide on Leakage-Independent Vision Loss in Fellow Eyes with Neovascular AMD in the ReCLAIM Study
Priyatham (Prithu) S Mettu, MD
Updates from the Field
2019
Elamipretide, a Mitochondrial-Targeted Drug, for the Treatment of Vision Loss in Dry AMD with High Risk Drusen
Michael J Allingham, MD, PhD
Annual Meeting Talks
2019
Mitochondria-Targeted Drug Elamipretide for Treatment of Vision Loss in Dry AMD With Noncentral Geographic Atrophy
Scott W. Cousins, MD
Annual Meeting Talks
2019
Elamipretide, a Mitochondria-Targeted Drug for the Treatment of Vision Loss
Scott W. Cousins, MD
Updates from the Field
2019